AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating ...

Overactivity of the JAK signalling pathway is believed to drive inflammation involved in the development and progression of vitiligo. New 52-week results from a dose-ranging phase 2b study of ...

Rottweilers are strong, loyal, and intelligent dogs. These gorgeous pups are usually black with tan or rust markings on their short, dense fur, and these markings usually appear above their eyes, on ...

Apr. 4, 2025 — Exposure to fine particulate air pollution (PM2.5) from wildfire smoke was associated with increased visits to emergency departments (ED) for mental health conditions, according ...

Mar. 12, 2025 — Experiencing five or more severe sunburns between the ages of 15 and 20 increases the risk of melanoma by 80% and nonmelanoma skin cancer by 68%. This study is among the few to ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.

About Povorcitinib Povorcitinib (INCB54707) is an oral small-molecule JAK1 selective inhibitor currently in Phase 3 clinical trials for HS, vitiligo and prurigo nodularis (PN), as well as Phase 2 ...